Table 1.
The baseline characteristics of patients
| Characteristic | No. (%) (n = 162) |
|---|---|
| Age (yr) | |
| Median | 64 |
| Range | 32–83 |
| Sex | |
| Male | 92 (57) |
| Female | 70 (43) |
| Smoking history | |
| Never-smoker | 83 (51) |
| Current | 33 (20) |
| Ex-smoker | 46 (28) |
| Histology | |
| Adenocarcinoma | 139 (86) |
| Squamous cell carcinoma | 17 (10) |
| Adenosquamous | 1 (1) |
| NSCLC, other | 5 (3) |
| Clinical stage | |
| I–II | 7 (4) |
| IIIA | 5 (3) |
| IIIB | 5 (3) |
| IV | 145 (90) |
| Brain metastasis | |
| Present | 49 (30) |
| Absent | 113 (70) |
| Biopsy type | |
| VATS | 45 (28) |
| CNB_lung | 23 (14) |
| CNB_others | 22 (14) |
| Bronchoscopy | 31 (19) |
| EBUS | 41 (25) |
| First treatment | |
| Chemotherapy | 81 (50) |
| EGFR TKI | 51 (32) |
| ALK TKI | 3 (2) |
| No treatment | 27 (16) |
NSCLC, non-small cell lung carcinoma; VATS, video-assisted thoracoscopic surgery; CNB, core-needle biopsy; EBUS, endobronchial ultrasonography; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ALK, anaplastic lymphoma kinase.